Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: A systematic review of phase i clinical trials

Leukemia and Lymphoma

Volumn 54, Issue 2, 2013, Pages 255-260

  Xu, Xiao Jun ^a,b   Zhao, Hai Zhao ^a,b   Tang, Yong Min ^a,b  

^a CHILDREN S HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; CD19; Chimeric antigen receptor; Leukemia; Lymphoma

Indexed keywords

BENDAMUSTINE; CD19 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE; GAMMA INTERFERON; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; PENTOSTATIN; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CAPILLARY LEAK SYNDROME; CELL EXPANSION; CHILL; CHIMERA; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEVER; HUMAN; HYPOTENSION; MEDLINE; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; REVIEW; RIGOR; SYSTEMATIC REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

ANTIGENS, CD19; CLINICAL TRIALS, PHASE I AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LEUKEMIA, B-CELL; LYMPHOMA, B-CELL; PROGNOSIS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84872027520     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.715350     Document Type: Review

References (45)

1. Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90: 51-81.
2. Ramos CA, Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opin Biol Ther 2011; 11: 855-873.
3. Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specificchimeric antigen receptor redirected Tcells in humans. Biol Blood Marrow Transplant 2010; 16: 1245-1256.
4. Pule MA, Savoldo B, Myers GD, et al. Virus-specificT cells engineered to coexpress tumor-specificreceptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14: 1264-1270.
5. Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified Tcells in lymphoma patients. JClin Invest 2011; 121: 1822-1826.
6. Kalos M, Levine BL, Porter DL, et al. Tcells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73.
7. Till BG, Jensen MC, Wang J, et al. CD20-specificadoptive immunotherapy for lymphoma using achimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 2012; 119: 3940-3950.
8. Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specificT lymphocytes with interleukin-15 and asuicide gene to enhance their antilymphoma/leukemia effects and safety. Leukemia 2010; 24: 1160-1170.
9. Singh H, Figliola MJ, Dawson MJ, et al. Reprogramming CD19-specificT cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res 2011; 71: 3516-3527.
10. Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted Tcells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119: 4133-4141.
11. Berger C, Jensen MC, Lansdorp PM, et al. Adoptive transfer of effector CD8-Tcells derived from central memory cells establishes persistent Tcell memory in primates. JClin Invest 2008; 118: 294-305.
12. James SE, Greenberg PD, Jensen MC, et al. Antigen sensitivity of CD22-specificchimeric TCR is modulated by target epitope distance from the cell membrane. JImmunol 2008; 180: 7028-7038.
13. Giordano Attianese GM, Marin V, Hoyos V, et al. In vitro and in vivo model of anovel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood 2011; 117: 4736-4745.
14. Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing atumor-specificchimeric antigen receptor. Blood 2010; 116: 1035-1044.
15. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human Tlymphocytes costimulated by CD80 and interleukin-15. Nat Med 2003; 9: 279-286.
16. Barrett DM, Zhao Y, Liu X, et al. Treatment of advanced leukemia in mice with mRNA engineered Tcells. Hum Gene Ther 2011; 22: 1575-1586.
17. Song DG, Ye Q, Carpenito C, et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered Tcells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 2011; 71: 4617-4627.
18. Kohn DB, Dotti G, Brentjens R, et al. CARs on track in the clinic. Mol Ther 2011; 19: 432-438.
19. Ertl HC, Zaia J, Rosenberg SA, et al. Considerations for the clinical application of chimeric antigen receptor Tcells: observations from arecombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Res 2011; 71: 3175-3181.
20. Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in aclinical trial of anti-CD19 chimeric-antigen-receptor-transduced Tcells. Blood 2012; 119: 2709-2720.
21. Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in apatient treated with autologous Tcells genetically engineered to recognize CD19. Blood 2010; 116: 4099-4102.
22. Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted Tcells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-4828.
23. Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptormodified Tcells in chronic lymphoid leukemia. NEngl JMed 2011; 365: 725-733.
24. Brentjens R, Yeh R, Bernal Y, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous Tcells: case report of an unforeseen adverse event in aphase Iclinical trial. Mol Ther 2010; 18: 666-668.
25. Burger JA, O'Brien S, Fowler N, et al. TheBruton'styrosine kinase inhibitor, PCI-32765, is well tolerated and demonstrates promising clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): an update on ongoing phase 1 studies. Blood 2010; 116(Suppl. 1): Abstract 57.
26. Fowler N, Sharman JP, Smith SM, et al. TheBtk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from aphase Istudy. Blood 2010; 116(Suppl. 1): Abstract 964.
27. Wang LH, Martin P, Blum KA, et al. TheBruton'styrosine kinase inhibitor PCI-32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of aphase II trial. Blood 2011; 118: 203-204.
28. Furman RR, Byrd JC, Brown JR, et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010; 116(Suppl. 1): Abstract 55.
29. Kahl B, Byrd JC, Flinn IW, et al. Clinical safety and activity in aphase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010; 116(Suppl. 1): Abstract 1777.
30. Roberts AW, Seymour JF, Brown JR, et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of aphase Istudy of navitoclax in patients with relapsed or refractory disease. JClin Oncol 2012; 30: 488-496.
31. Doti CA, Bullorsky EO. Hematopoietic stem cell transplantation in the era of tyrosine kinase inhibitors. Leuk Lymphoma 2009; 50(Suppl. 2): 27-31.
32. Cui Y, Zhang H, Meadors J, et al. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood 2009; 114: 3831-3840.
33. Wrzesinski C, Paulos CM, Kaiser A, et al. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specificT cells. JImmunother 2010; 33: 1-7.
34. Caserta S, Alessi P, Basso V, et al. IL-7 is superior to IL-2 for ex vivo expansion of tumour-specificCD4(-) Tcells. Eur JImmunol 2010; 40: 470-479.
35. Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted Tcells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119: 4133-4141.
36. Louis CU, Savoldo B, Dotti G, et al. Antitumor activity and longterm fate of chimeric antigen receptor-positive Tcells in patients with neuroblastoma. Blood 2011; 118: 6050-6056.
37. Li Z, Dullmann J, Schiedlmeier B, et al. Murine leukemia induced by retroviral gene marking. Science 2002; 296: 497.
38. Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. Aserious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. NEngl JMed 2003; 348: 255-256.
39. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2-associated clonal Tcell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
40. Newrzela S, Cornils K, Li Z, et al. Resistance of mature Tcells to oncogene transformation. Blood 2008; 112: 2278-2286.
41. Recchia A, Bonini C, Magnani Z, et al. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted Tcells. Proc Natl Acad Sci USA 2006; 103: 1457-1462.
42. Walker RE, Bechtel CM, Natarajan V, et al. Long-term in vivo survival of receptor-modified syngeneic Tcells in patients with human immunodeficiency virus infection. Blood 2000; 96: 467-474.
43. Mitsuyasu RT, Anton PA, Deeks SG, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(-) and CD8(-) Tcells in human immunodeficiency virus-infected subjects. Blood 2000; 96: 785-793.
44. Khaleghi S, Rahbarizadeh F, Ahmadvand D, et al. Acaspase 8-based suicide switch induces apoptosis in nanobody-directed chimeric receptor expressing Tcells. Int JHematol 2012; 95: 434-444.
45. Tey SK, Dotti G, Rooney CM, et al. Inducible caspase 9 suicide gene to improve the safety of allodepleted Tcells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 913-924.